Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Claudia Haferlach, Gudrun Göhring et al.|Blood|2011Cited by 289
Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saußele, Martin C. Müller, Marie-Paloma Krauß et al.|Blood|2015Cited by 200
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (<i>JAK2</i>) V617F and KIT proto‐oncogene, receptor tyrosine kinase (<i>KIT</i>) D816V mutationsNicole Naumann, Juliana Schwaab, Johannes Lübke et al.|British Journal of Haematology|2021Cited by 17